The Quantellect read.As of Nov 19, 2026, 15 active firms cover Tenet Healthcare Corporation: 13 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $225.00 to $309.00, so the covering firms are broadly aligned. The average target of $274.80 sits 1% above the current $271.42. The rating mix has stayed broadly stable, with Buy-side ratings easing from 17 to 13 over recent months. On the fundamentals, the Street sees consensus EPS building from about $4.53 next quarter toward $20.32 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS15 active firms
Buy
Strong Buy00%
Buy1387%
Neutral213%
Sell00%
Strong Sell00%
Based on 15 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$274.80
+1.2% upside
Average target across 15 active firms as of Nov 19, 2026 vs $271.42 current
Highest Target$309.00
Average Target$274.80
Lowest Target$225.00
Detailed analyst forecasts for THC
Showing 1–15 of 15 named analysts shown · 15 active firms in the rating projection
As of Nov 19, 2026, 13 of 15 active firms rate THC a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
THC EPS & revenue forecast
EPS · NEXT QUARTER
$4.53
Range $3.85 – $5.34 · 12 analysts · -6% YoY
Next period, 12 analysts expect Tenet Healthcare Corporation to earn $4.53 a share (range $3.85 – $5.34), versus $4.82 a year earlier. Full-year consensus is $22.57, growing to $20.32 the year after.
REVENUE · NEXT QUARTER
$5.5B
Range $5.3B – $5.7B · 12 analysts · +2% YoY
Revenue is expected to reach $5.5B (range $5.3B – $5.7B), +1.7% year-over-year. Full-year consensus is $22.3B, rising to $22.5B next year.
Top analysts covering Tenet Healthcare Corporation
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on THC.
#1
Stephen Baxter
Wells Fargo · Rank #63
Buy
$321.00+18.3% to target
Overall win rate
47%
+ Follow
#2
DM
David Macdonald
Truist Securities · Rank #111
Buy
$290.00+6.8% to target
Overall win rate
50%
+ Follow
#3
Ben Hendrix
RBC Capital · Rank #150
Buy
$304.00+12.0% to target
Overall win rate
44%
+ Follow
#4
Sarah James
Cantor Fitzgerald · Rank #159
Buy
$245.00-9.7% to target
Overall win rate
37%
+ Follow
#5
Brian Tanquilut
Jefferies · Rank #280
Buy
$265.00-2.4% to target
Overall win rate
46%
+ Follow
THC stock forecast FAQ
What is THC's average 12-month price target?+
The 15 active firms with a live target average $274.80 for Tenet Healthcare Corporation over the next 12 months, ranging from a $309.00 high to a $225.00 low, as of Nov 19, 2026.
Is THC stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 15 active firms as of Nov 19, 2026, 13 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for THC?+
The Street-high target is $309.00 (Leerink Partners), and the Street-low is $225.00 (Keybanc). The average of all 15 active-firm targets is $274.80.
How many active Wall Street firms cover THC?+
15 active firms have a recognized rating on Tenet Healthcare Corporation as of Nov 19, 2026, and 15 active firms carry a live 12-month price target.
Who is the most accurate analyst covering THC?+
Among analysts who currently cover THC, Stephen Baxter of Wells Fargo has the strongest overall Quantellect track record (Rank #63). Their current call is Buy with a $321.00 target.
What is Tenet Healthcare Corporation's projected EPS for next quarter?+
The consensus estimate is $4.53 per share (range $3.85 – $5.34) across 12 analysts. Full-year EPS is projected at $22.57, rising to $20.32 the following year.
How much revenue is Tenet Healthcare Corporation expected to report next quarter?+
Consensus revenue is $5.5B (range $5.3B – $5.7B). Full-year revenue is projected at $22.3B, growing to $22.5B next year.
Have analysts been upgrading or downgrading THC lately?+
As of Nov 19, 2026, 13 of 15 active firms rate THC a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their THC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.